Grifols Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Grifols ha un patrimonio netto totale di €8.0B e un debito totale di €9.9B, che porta il suo rapporto debito/patrimonio netto a 123.2%. Le sue attività totali e le sue passività totali sono rispettivamente €20.3B e €12.3B. L'EBIT di Grifols è €971.7M rendendo il suo rapporto di copertura degli interessi 1.8. Ha liquidità e investimenti a breve termine pari a €806.7M.

Informazioni chiave

123.2%

Rapporto debito/patrimonio netto

€9.85b

Debito

Indice di copertura degli interessi	1.8x
Contanti	€806.74m
Patrimonio netto	€8.00b
Totale passività	€12.29b
Totale attività	€20.28b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €5.3B ) di GRF.P superano le sue passività a breve termine ( €2.4B ).

Passività a lungo termine: Le attività a breve termine di GRF.P ( €5.3B ) non coprono le sue passività a lungo termine ( €9.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 113.1% ) di GRF.P è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di GRF.P si è ridotto da 138.3% a 123.2% negli ultimi 5 anni.

Copertura del debito: Il debito di GRF.P non è ben coperto dal flusso di cassa operativo ( 5.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di GRF.P non sono ben coperti dall'EBIT ( 1.8 x copertura).

Grifols Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane